产品
编 号：F625746
分子式：C23H17F3N4O3S2
分子量：518.53
分子式：C23H17F3N4O3S2
分子量：518.53
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
结构图
CAS No: 1242422-09-8
产品详情
生物活性：
SSTC3 is a casein kinase 1α (CK1α) activator (Kd = 32 nM) that inhibits WNT signaling (EC50 = 30 nM). SSTC3 exhibits minimal gastrointestinal toxicity compared to other classes of WNT inhibitors.
体内研究：
SSTC3 can be maintained for 24 hours after treatment.SSTC3 (25 mg/kg, ip once daily for 8-12 days) suppresses the growth of colorectal carcinoma in CD-1 mice.SSTC3 (10 mg/kg, ip once daily for 1 month) inhibits the growth of Apc mutation-driven tumors.Animal Model:Five-week-old Apcmin mice.
Dosage:10 mg/kg.
Administration:IP for 1 month.
Result:Inhibited the growth of Apc mutation-driven tumors.
Animal Model:CD-1 mice.
Dosage:25 mg/kg.
Administration:IP once daily for 8-12 days.
Result:Inhibited the growth of HCT116 xenografts.Attenuated the growth of this metastatic CRC PDX and markedly reduced the cell density of residual cancer. Reduced the expression of WNT biomarkers in this CRC PDX.
体外研究：
SSTC3 (0-1μM, 5 days) decreases the viability of HCT116 cells in an on-target manner. This capacity is significantly reduced when the mutant CTNNB1 allele driving its carcinogenic properties is deleted.
SSTC3 is a casein kinase 1α (CK1α) activator (Kd = 32 nM) that inhibits WNT signaling (EC50 = 30 nM). SSTC3 exhibits minimal gastrointestinal toxicity compared to other classes of WNT inhibitors.
体内研究：
SSTC3 can be maintained for 24 hours after treatment.SSTC3 (25 mg/kg, ip once daily for 8-12 days) suppresses the growth of colorectal carcinoma in CD-1 mice.SSTC3 (10 mg/kg, ip once daily for 1 month) inhibits the growth of Apc mutation-driven tumors.Animal Model:Five-week-old Apcmin mice.
Dosage:10 mg/kg.
Administration:IP for 1 month.
Result:Inhibited the growth of Apc mutation-driven tumors.
Animal Model:CD-1 mice.
Dosage:25 mg/kg.
Administration:IP once daily for 8-12 days.
Result:Inhibited the growth of HCT116 xenografts.Attenuated the growth of this metastatic CRC PDX and markedly reduced the cell density of residual cancer. Reduced the expression of WNT biomarkers in this CRC PDX.
体外研究：
SSTC3 (0-1μM, 5 days) decreases the viability of HCT116 cells in an on-target manner. This capacity is significantly reduced when the mutant CTNNB1 allele driving its carcinogenic properties is deleted.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备